Search Results | Blood | American Society of Hematology

1-20 of 78

2 3 4

Sort by

Sort Order Select

Journal Articles

The Prognostic Impact of FLT3 in NPM1 -Mutated AML: Co-Occurrence of FLT3-ITD and FLT3-TKD Confers Poor Outcomes

Onyee Chan, Najla Al Ali, Somedeb Ball, Justin Grenet, Caroline Hana, Yehuda E. Deutsch, Hammad Tashkandi, Ling Zhang, Mohammad O Hussaini, Seongseok Yun, Andrew Kuykendall, Eric Padron, Gail J. Roboz, Pinkal Desai, Rami S. Komrokji, Kendra Sweet, Jeffrey E. Lancet, David A. Sallman

Blood (2022) 140 (Supplement 1): 3435–3437.

DOI: https://doi.org/10.1182/blood-2022-171197

Published: 2022

Journal Articles

A Product of "Clash of Titans" or True Reflection of Disease Biology? Validation of 2022 WHO and ICC Classifications in a Large Dataset of Patients with Myelodysplastic Syndrome

Somedeb Ball, Avani M Singh, Najla Al Ali, Luis E. Aguirre, Akriti G Jain, Zaker I. Schwabkey, Sara M Tinsley-Vance, Onyee Chan, Andrew Kuykendall, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, David A. Sallman, Rami S. Komrokji

Blood (2022) 140 (Supplement 1): 1118–1120.

DOI: https://doi.org/10.1182/blood-2022-170158

Published: 2022

Journal Articles

Clinical Characterization and Outcomes of Patients with NPM1 -Mutated Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Chen Wang, Onyee Chan, Najla Al Ali, Andrew Kuykendall, Eric Padron, Kendra Sweet, Jeffrey E. Lancet, Rami S. Komrokji, David A. Sallman

Blood (2022) 140 (Supplement 1): 6936–6937.

DOI: https://doi.org/10.1182/blood-2022-160464

Published: 2022

Journal Articles

Luspatercept for Treatment of Lower Risk Myelodysplastic Syndromes: Real World Data Replicates Medalist Study Results and Confirms Activity Among Hypomethylating Agents and Lenalidomide Treated Patients

Rami S. Komrokji, Najla Al Ali, Somedeb Ball, Onyee Chan, Andrew Kuykendall, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, David A. Sallman

Blood (2022) 140 (Supplement 1): 4039–4041.

DOI: https://doi.org/10.1182/blood-2022-169690

Published: 2022

Journal Articles

Characterization of TP53 -Mutated Myelodysplastic Syndromes and Impact of Allelic Status and Concurrent Cytogenetic Abnormalities on Survival Outcomes

Luis E. Aguirre, Najla Al Ali, Akriti G Jain, Onyee Chan, Somedeb Ball, Andrew Kuykendall, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, Rami S. Komrokji, David A. Sallman

Blood (2022) 140 (Supplement 1): 4034–4035.

DOI: https://doi.org/10.1182/blood-2022-171093

Published: 2022

Journal Articles

Hypoplastic MDS: Validation of the New World Health Organization 2022 Proposal

Zaker I. Schwabkey, Amin Azem, Najla Al Ali, Somedeb Ball, Luis E. Aguirre, Akriti G Jain, Avani M Singh, Sara M Tinsley-Vance, Onyee Chan, Jeffrey E. Lancet, Kendra Sweet, Andrew Kuykendall, Eric Padron, David A. Sallman, Rami S. Komrokji

Blood (2022) 140 (Supplement 1): 6974–6975.

DOI: https://doi.org/10.1182/blood-2022-156974

Published: 2022

Journal Articles

Secondary AML Mutations Confer Poor Prognosis in Patients with ELN Favorable Risk NPM1 -Mutated AML

Blood (2022) 140 (Supplement 1): 3419–3421.

DOI: https://doi.org/10.1182/blood-2022-165802

Published: 2022

Journal Articles

Validation of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model for Myelodysplastic Syndromes

Luis E. Aguirre, Najla Al Ali, Somedeb Ball, Avani M Singh, Akriti G Jain, Onyee Chan, Zaker I. Schwabkey, Sara M Tinsley-Vance, Andrew Kuykendall, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, David A. Sallman, Rami S. Komrokji

Blood (2022) 140 (Supplement 1): 1125–1127.

DOI: https://doi.org/10.1182/blood-2022-170878

Published: 2022

Journal Articles

Treatments and Outcomes for Patients at Academic Cancer Centers with Myelodysplastic Syndrome (MDS) By Revised International Prognostic Scoring System (IPSS-R) Scores

Connor Willis, David A. Sallman, Malinda Tan, Madeline Brendle, Vonetta L. Williams, Craig Comperatore, Trang Au, Srinivas K. Tantravahi, Najla Al Ali, Jeffrey A. Gilreath, Tibor Kovacsovics, Xiting Cao, Islam Sadek, Rami S. Komrokji, David Stenehjem

Blood (2022) 140 (Supplement 1): 5291–5292.

DOI: https://doi.org/10.1182/blood-2022-162622

Published: 2022

Journal Articles

Synergistic Activity of Luspatercept and Erythroid Stimulating Agents Combination for Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes

Rami S. Komrokji, Luis E. Aguirre, Najla Al Ali, Onyee Chan, Andrew Kuykendall, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, David A. Sallman

Blood (2022) 140 (Supplement 1): 6917–6919.

DOI: https://doi.org/10.1182/blood-2022-169560

Published: 2022

Journal Articles

Assessment of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model in Hypoplastic Myelodysplastic Syndromes

Blood (2022) 140 (Supplement 1): 6909–6911.

DOI: https://doi.org/10.1182/blood-2022-171044

Published: 2022

Journal Articles

The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias

Blood (2022) 140 (Supplement 1): 2887–2890.

DOI: https://doi.org/10.1182/blood-2022-162367

Published: 2022

Journal Articles

Assessment of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model in Therapy-Related Myelodysplastic Syndromes

Blood (2022) 140 (Supplement 1): 9813–9815.

DOI: https://doi.org/10.1182/blood-2022-170980

Published: 2022

Journal Articles

Toxicity and Outcomes in Octo- and Nonagenarians with AML Treated with Venetoclax and Hypomethylating Agent Therapy

Blood (2022) 140 (Supplement 1): 3306–3308.

DOI: https://doi.org/10.1182/blood-2022-170771

Published: 2022

Journal Articles

Clone Size By Conventional Cytogenetics in Myelodysplastic Syndromes Correlates with Clinical Features and Outcomes

Rami S. Komrokji, Najla Al Ali, Virginia Olivia Volpe, Onyee Chan, Andrew Kuykendall, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, David A. Sallman

Blood (2022) 140 (Supplement 1): 9804–9805.

DOI: https://doi.org/10.1182/blood-2022-168439

Published: 2022

Journal Articles

Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)

Blood (2021) 138 (Supplement 1): 246.

DOI: https://doi.org/10.1182/blood-2021-153286

Published: 2021

Journal Articles

Assessing the Role of Venetoclax in Combination with Hypomethylating Agents in Higher Risk Myelodysplastic Syndromes

Rami S. Komrokji, Najla Al Ali, Onyee Chan, Eric Padron, Kendra Sweet, Andrew T. Kuykendall, Jeffrey E. Lancet, David A. Sallman

Blood (2021) 138 (Supplement 1): 536.

DOI: https://doi.org/10.1182/blood-2021-146634

Published: 2021

Journal Articles

Mutations Highly Specific for Secondary AML Are Associated with Poor Outcomes in Patients with NPM1 -Mutated ELN Favorable Risk AML

Onyee Chan, Najla Al Ali, Hammad Tashkandi, Austin Ellis, Somedeb Ball, Ling Zhang, Mohammad Hussaini, Jinming Song, Seongseok Yun, Chetasi Talati, Andrew T. Kuykendall, Eric Padron, David A. Sallman, Kendra Sweet, Rami S. Komrokji, Jeffrey E. Lancet

Blood (2021) 138 (Supplement 1): 686.

DOI: https://doi.org/10.1182/blood-2021-150759

Published: 2021

Journal Articles

Different Treatment Approaches to Blast Phase-Myeloproliferative Neoplasms

Franco Castillo Tokumori, Najla Al Ali, Onyee Chan, David A. Sallman, Seongseok Yun, Kendra Sweet, Eric Padron, Jeffrey E. Lancet, Rami S. Komrokji, Andrew T. Kuykendall

Blood (2021) 138 (Supplement 1): 3641.

DOI: https://doi.org/10.1182/blood-2021-146945

Published: 2021

Journal Articles

Differential Prognostic Impact of IDH1 and IDH2 Mutations in Chronic Myelomonocytic Leukemia

Connor M. Walsh, Anthony Hunter, Terra Lasho, Christy Finke, Rami S. Komrokji, Mithun V. Shah, Ayalew Tefferi, Abhishek A. Mangaonkar, Matthew T Howard, Naseema Gangat, Aref Al-Kali, Najla Al Ali, Eric Padron, Mrinal M. Patnaik

Blood (2021) 138 (Supplement 1): 3684.

DOI: https://doi.org/10.1182/blood-2021-150786

Published: 2021

2 3 4

NARROW

The Prognostic Impact of FLT3 in NPM1 -Mutated AML: Co-Occurrence of FLT3-ITD and FLT3-TKD Confers Poor Outcomes

A Product of "Clash of Titans" or True Reflection of Disease Biology? Validation of 2022 WHO and ICC Classifications in a Large Dataset of Patients with Myelodysplastic Syndrome

Clinical Characterization and Outcomes of Patients with NPM1 -Mutated Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Luspatercept for Treatment of Lower Risk Myelodysplastic Syndromes: Real World Data Replicates Medalist Study Results and Confirms Activity Among Hypomethylating Agents and Lenalidomide Treated Patients

Characterization of TP53 -Mutated Myelodysplastic Syndromes and Impact of Allelic Status and Concurrent Cytogenetic Abnormalities on Survival Outcomes

Hypoplastic MDS: Validation of the New World Health Organization 2022 Proposal

Secondary AML Mutations Confer Poor Prognosis in Patients with ELN Favorable Risk NPM1 -Mutated AML

Validation of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model for Myelodysplastic Syndromes

Treatments and Outcomes for Patients at Academic Cancer Centers with Myelodysplastic Syndrome (MDS) By Revised International Prognostic Scoring System (IPSS-R) Scores

Synergistic Activity of Luspatercept and Erythroid Stimulating Agents Combination for Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes

Assessment of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model in Hypoplastic Myelodysplastic Syndromes

The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias

Assessment of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model in Therapy-Related Myelodysplastic Syndromes

Toxicity and Outcomes in Octo- and Nonagenarians with AML Treated with Venetoclax and Hypomethylating Agent Therapy

Clone Size By Conventional Cytogenetics in Myelodysplastic Syndromes Correlates with Clinical Features and Outcomes

Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)

Assessing the Role of Venetoclax in Combination with Hypomethylating Agents in Higher Risk Myelodysplastic Syndromes

Mutations Highly Specific for Secondary AML Are Associated with Poor Outcomes in Patients with NPM1 -Mutated ELN Favorable Risk AML

Different Treatment Approaches to Blast Phase-Myeloproliferative Neoplasms

Differential Prognostic Impact of IDH1 and IDH2 Mutations in Chronic Myelomonocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only